Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience

Leuk Lymphoma. 2020 Dec;61(13):3255-3258. doi: 10.1080/10428194.2020.1802452. Epub 2020 Aug 10.

Affiliations

¹ Haematology Unit, Careggi University Hospital, Florence, Italy.
² Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.
³ Nephrology, Dialysis and Transplantation Unit, Careggi Hospital, Firenze, Italy.
⁴ Cell Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence, Italy.

PMID: 32772601
DOI: 10.1080/10428194.2020.1802452

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Lenalidomide / therapeutic use
Multiple Myeloma* / drug therapy

Substances

Antibodies, Monoclonal
daratumumab
Dexamethasone
Lenalidomide